- Home
- BPMC
as 07-26-2024 4:00pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Upcoming Earnings Alert:
Get ready for potential market movements as Blueprint Medicines Corporation BPMC prepares to release earnings report on 01 Aug 2024.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 6.5B | IPO Year: | 2015 |
| Target Price: | $116.33 | AVG Volume (30 days): | 625.0K |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $43.89 - $121.90 | Next Earning Date: | 08-01-2024 |
| Revenue: | $282,209,000 | Revenue Growth: | 37.94% |
| Revenue Growth (this year): | 75.7% | Revenue Growth (next year): | 50.89% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jul 3 '24 | Sell | $111.20 | 3,850 | $428,120.00 | 43,763 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jul 3 '24 | Sell | $111.29 | 8,817 | $981,243.93 | 43,763 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jun 28 '24 | Sell | $111.15 | 333 | $37,012.95 | 43,763 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jun 21 '24 | Sell | $102.44 | 300 | $30,732.00 | 43,763 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jun 21 '24 | Sell | $103.05 | 13,062 | $1,346,039.10 | 44,063 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jun 21 '24 | Sell | $104.14 | 40,353 | $4,202,361.42 | 57,125 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jun 21 '24 | Sell | $104.98 | 18,752 | $1,968,584.96 | 97,478 | SEC Form 4 |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Jun 21 '24 | Sell | $105.82 | 1,567 | $165,819.94 | 116,230 | SEC Form 4 |
| Carter Percy H. | BPMC | CHIEF SCIENTIFIC OFFICER | Jun 5 '24 | Sell | $105.13 | 4,000 | $420,520.00 | 41,895 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | Jun 4 '24 | Sell | $104.91 | 2,424 | $254,301.84 | 29,514 | SEC Form 4 |
| Carter Percy H. | BPMC | CHIEF SCIENTIFIC OFFICER | Jun 3 '24 | Sell | $106.43 | 2,436 | $259,263.48 | 45,895 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | May 31 '24 | Sell | $106.43 | 1,951 | $207,644.93 | 31,938 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | May 31 '24 | Sell | $106.43 | 2,971 | $316,203.53 | 33,889 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | May 31 '24 | Sell | $104.83 | 6,342 | $664,831.86 | 36,860 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | May 31 '24 | Sell | $105.81 | 20,904 | $2,211,852.24 | 43,202 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | May 31 '24 | Sell | $106.50 | 3,191 | $339,841.50 | 64,106 | SEC Form 4 |
| Hewes L. Becker | BPMC | CHIEF MEDICAL OFFICER | May 31 '24 | Sell | $107.86 | 3,671 | $395,954.06 | 67,297 | SEC Form 4 |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 15 '24 | Sell | $107.22 | 3,582 | $384,062.04 | 17,187 | SEC Form 4 |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 15 '24 | Sell | $106.56 | 2,274 | $242,317.44 | 14,913 | SEC Form 4 |
| Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | May 15 '24 | Sell | $107.17 | 2,486 | $266,424.62 | 72,981 | SEC Form 4 |
| Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | May 15 '24 | Sell | $106.56 | 1,364 | $145,347.84 | 71,617 | SEC Form 4 |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 2 '24 | Sell | $103.88 | 1,834 | $190,515.92 | 14,913 | SEC Form 4 |
| Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | May 2 '24 | Sell | $105.00 | 10,000 | $1,050,000.00 | 47,286 | SEC Form 4 |
| Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | Mar 28 '24 | Sell | $95.00 | 5,000 | $475,000.00 | 47,286 | SEC Form 4 |
| Albers Jeffrey W. | BPMC | Director | Mar 20 '24 | Sell | $89.12 | 1,367 | $121,827.04 | 176,050 | SEC Form 4 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
PR Newswire
9 days ago
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
MT Newswires
18 days ago
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating
MT Newswires
a month ago
Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing
Investor's Business Daily
a month ago
How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'
GuruFocus.com
2 months ago
Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
MT Newswires
2 months ago
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
GuruFocus.com
2 months ago
Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.